The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 07, 2018

Filed:

Jan. 08, 2016
Applicant:

Warp Drive Bio, Inc., Cambridge, MA (US);

Inventors:

Gregory Lawrence Verdine, Bedford, MA (US);

Matthew James Nichols, Charlestown, MA (US);

Dylan Talbot Stiles, Cambridge, MA (US);

Neville John Anthony, Northborough, MA (US);

Brian Roger Bowman, New Rochelle, NY (US);

Mathew Edward Sowa, Watertown, MA (US);

Sharon Ann Townson, Cambridge, MA (US);

Assignee:

Warp Drive Bio, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); A61K 47/48 (2006.01); C07D 498/18 (2006.01); C07K 7/64 (2006.01); C07K 7/56 (2006.01); C07D 405/06 (2006.01); C07D 498/22 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48346 (2013.01); C07D 405/06 (2013.01); C07D 498/18 (2013.01); C07D 498/22 (2013.01); C07K 7/56 (2013.01); C07K 7/64 (2013.01); C07K 7/645 (2013.01);
Abstract

The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention 're-program' the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.


Find Patent Forward Citations

Loading…